No profile data available.
Nasus Pharma Ltd. (NSRX) is a healthcare company in the allergy treatment pharmaceuticals industry, based in Tel Aviv-Yafo, Israel, with about 7 full-time employees.
It reported revenue of $0 for fiscal year 2024, and net income of -$1.53 million. Its market capitalization was $41.12 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Nasus Pharma reported $0 in revenue for fiscal year 2024.
$41.12 million as of October 9, 2026.
Listed companies of a similar size in the same industry (allergy treatment pharmaceuticals) include Rapt Therapeutics, Inc. (RAPT), DBV Technologies S.a. (DBVT), ARS Pharmaceuticals, Inc. (SPRY).